Skip to content
Not yet recruitingPhase 2

Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

NCT07565909 · University of Washington

Closed to entry
Status
Not accepting participants
Phase 2
Phase
72
Target enrolment
Study sites

What it is testing

Summary

In this single-arm Phase 2 study, the researchers are assessing the feasibility of the group retreat format for clinicians and explores different 'doses' of preparation. A sequential dose-escalation design is used. The study will recruit healthcare clinicians (physicians, nurses, nurse practitioners, physician assistants) aged 25-70 years currently in clinical practice with moderate or greater symptoms of depression and loss of meaning during the past 5 years. Each participant will be in a group cohort of 8, and 3 cohorts will be tested at each dose level. The objectives are safety, feasibility, mechanism testing, and outcomes.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Safety and Feasibility measures

    Measured over 1 week, 1 month, and 3 months after the retreat.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

25 Years to 70 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Healthcare clinicians (physicians, nurses, nurse practitioners, physician assistants) currently in clinical practice 2. Age 25-70 years 3. Loss of meaning single question "I used to find deep meaning in my work as a healthcare clinician, but during the past 5 years that sense of meaning has faded". 4. PHQ-9 score ≥10 (moderate symptoms of depression) 5. Ability to commit to all preparation sessions and retreat attendance 6. English fluency sufficient for group participation 7. Screening laboratory tests within acceptable limits, including liver function tests 8. Negative urine drug screen for non-prescribed psychoactive medications. 9. ECG with QTc \<450 ms 10. Willing to taper and discontinue any supplements with serotonin-like properties, including but not limited to 5-HTP, St. John's Wort, and 'brain food' supplements. 11. For participants of childbearing potential, agree to use to use highly effective contraception. Highly effective contraceptive methods are defined as those that, alone or in combination, result in a low failure rate (less than 1 percent per year), including but not limited to implants, IUDs, contraceptive injections, or contraceptive pills. Exclusion Criteria: 1. Personal or first-degree family history of psychotic disorder or bipolar I disorder 2. Personal major depressive episode prior to entering healthcare as a professional 3. Active suicidal ideation with intent or plan 4. Unstable medical conditions 5. Pregnancy or breastfeeding 6. Hypertension with BP systolic \>150 or diastolic \> 90

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07565909 on ClinicalTrials.gov →

Last updated in the registry 2026-05-04. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits